RESEARCH MONOGRAPH · KDC-MN-064

Mexidol (Emoxypine)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

Russian antioxidant that's part real mitochondrial protectant, part everything-bagel hospital drug

Mexidol (emoxypine succinate, 2-ethyl-6-methyl-3-hydroxypyridine succinate) is prescribed for basically every neurological complaint in Russia, which is both a tell and a problem. When a drug is approved for stroke, TBI, anxiety, alcohol withdrawal, ischemic heart disease, and post-COVID cognitive complaints, you should be suspicious. But the underlying mechanism is actually interesting enough to take seriously.

The molecule is a pyridine hydroxyl radical scavenger conjugated to succinate, which is the clever part. Succinate is a Complex II substrate, so you're delivering a membrane-permeable antioxidant alongside a TCA cycle intermediate that can bypass certain mitochondrial dysfunction states. The Lukyanova group at the Institute of General Pathology has published quite a bit on hypoxia-tolerance phenotypes responding to succinate-based interventions, and emoxypine fits that picture.

What we like is that the preclinical mitochondrial biology is genuinely real. In ischemia-reperfusion models, the antioxidant + succinate combo does outperform either alone. The pyridine moiety scavenges lipid peroxidation products, and the succinate component helps maintain ATP production when Complex I is impaired. Thats a reasonable mechanism for the stroke and TBI indications.

What we dont like is everything else. The clinical trial literature is mostly Russian-language, mostly underpowered, and the indications creep is borderline ridiculous. The recent western meta-analyses on Mexidol for ischemic stroke are unimpressive once you weight for trial quality, and the post-COVID indication is pure regulatory opportunism.

Sourcing-wise, the pure compound is straightforward to make and HPLC well, and as a research reagent for studying succinate-pyridine antioxidant chemistry it's perfectly fine. The actual Russian pharmaceutical product (ampules from Pharmasoft) is a different beast and not what we're talking about here.

Honestly, this is a compound where the chemistry is more interesting than the clinical story. If you're studying mitochondrial antioxidants or hypoxia-tolerance pathways, emoxypine succinate is a useful tool compound. If you're looking at it as a generic neuroprotectant, the evidence is weaker than the marketing.

Evidence: 40
Mechanism: 70
Reliability: 50
Safety: 80
Sourcing: 72
Value: 68
Signal: 50
Staying power: 45

Plain-language summary Intrigue 55 / 100

Mexidol (emoxypine) is a Russian antioxidant pyridine derivative used widely in former Soviet states for stroke, brain injury, and cognitive impairment. Available as injection and oral. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Pyridine antioxidant

A Russian-developed pyridine antioxidant (2-ethyl-6-methyl-3-hydroxypyridine succinate) widely prescribed in Russia for cerebrovascular and cognitive disorders.

Abstract

Mexidol (Emoxypine succinate; 2-ethyl-6-methyl-3-hydroxypyridine succinate; CAS 127464-43-1) is a pyridine-class antioxidant developed in the Soviet Union in the 1980s and approved in Russia for cerebrovascular insufficiency, cognitive impairment, and acute neurological events including stroke. The compound combines a 3-hydroxypyridine antioxidant (emoxypine) with succinate as the metabolic energy substrate. Mechanism is multimodal: free radical scavenging, membrane phospholipid stabilization, succinate-driven mitochondrial substrate provision under conditions of compromised respiratory chain function, and modest GABA-A allosteric modulation. The compound is described in the research literature as administered orally or parenterally. Reported research dose ranges in the literature are described in the source monograph. The Russian clinical evidence base is extensive (used in tens of thousands of patients) but Western-grade randomized trials with standard endpoints are limited.

Mechanism of action

Multimodal: 3-hydroxypyridine free radical scavenging, membrane stabilization, succinate substrate provision, modest GABA-A allosteric modulation.

Reported research dose ranges

250 to 500 mg (reported research dose range) oral; 100 to 500 mg (reported research dose range) parenteral.

References

Voronina TA. Mexidol: spectrum of action and mechanism. Russian J Pharmacol 2000s.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-064

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Mexidol (Emoxypine)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs